Erectile Dysfunction Clinical Trial
Official title:
A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RALP) - Effect on Potency Outcomes
NCT number | NCT02526173 |
Other study ID # | AFRLP003 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 1, 2015 |
Est. completion date | June 21, 2018 |
Verified date | September 2018 |
Source | MiMedx Group, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will examine the beneficial impacts of applying of dHACM on the preserved neurovascular bundles (cavernosal nerves) and the prostate bed during robotic assisted laparoscopic prostatectomy. Such application can result in promotion of soft tissue healing and reduction of inflammation at the operative site and thus an acceleration of return of potency regulating cavernosal nerves.
Status | Completed |
Enrollment | 230 |
Est. completion date | June 21, 2018 |
Est. primary completion date | June 21, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Male subjects between the ages 40-70. 2. Primary diagnosis of prostate cancer requiring surgical intervention 3. Have a willingness to comply with follow-up examination 4. Have ability to provide full written consent 5. Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, 7,8 or 9 6. Planned elective radical prostatectomy with bilateral full nerve sparing technique 7. Patients who currently have a pre-operative SHIM > 19 8. Negative urinalysis within 7 days prior to date of surgery Exclusion Criteria: 1. Has signs or symptoms of any other disease which could result in allograft failure, or has experienced graft failure in the past 2. Has any condition(s), which seriously compromises the subject's ability to participate in this study, or has a known history of poor adherence with medical treatment 3. Has comorbid conditions that can be confused with or can exacerbate the condition, including diabetes or Advanced atherosclerotic vascular disease 4. Is unable to sign or understand informed consent 5. Is unable to comply with penile rehabilitation, including oral 5-phosphodiesterase inhibitor 6. Has a history of drug or alcohol abuse within last 12 months 7. Has autoimmune disease or a known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV 8. Is allergic to Aminoglycoside antibiotics (such as Gentamicin and/or Streptomycin) 9. Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study 10. Patients currently enrolled in another study. Concurrent enrollment in another study is prohibited 11. Has had prior hormonal therapy such as Lupron or oral anti-androgens 12. Living outside of United States 13. Partial nerve sparing technique used during Radical Prostatectomy |
Country | Name | City | State |
---|---|---|---|
United States | Florida Hospital: Global Robotics Institute | Celebration | Florida |
Lead Sponsor | Collaborator |
---|---|
MiMedx Group, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Potency as assessed by Sexual Health Inventory for Men (SHIM) Score | As measured by SHIM | 12 months | |
Primary | Return to sexual function | Patient directed questionnaire | 12 months | |
Secondary | Continence | As assessed by American Urological Association (AUA) score | 12 months | |
Secondary | Continence | Patient directed questionnaire | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 |